Jazz Pharmaceuticals PLC Form 4 insider transactions

Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals plc, reported a transaction in 780 shares of common stock on August 5, 2026.

Rick E Winningham, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Ted W Love, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Laura Hamill, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Patrick Kennedy, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Mark Douglas Smith, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Jennifer E. Cook, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Seamus Mulligan, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Heather Ann Mcsharry, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Patrick G Enright, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Norbert G Riedel, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, received 1,605 shares of common stock on August 5, 2026.

Bruce C Cozadd, a Director of Jazz Pharmaceuticals plc, sold 6,000 shares of common stock on August 3, 2026 for $252.98 per share.

Jazz Pharmaceuticals Director Bruce C. Cozadd sold 6,000 ordinary shares on July 1, 2026, under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals executive Samantha Pearce reported a disposition of ordinary shares, primarily to cover tax obligations.

Renee D. Gala, President & CEO of Jazz Pharmaceuticals, reported a transaction involving the sale of ordinary shares.

Jazz Pharmaceuticals plc reports a transaction where EVP Robert Iannone sold shares to cover tax obligations.

Jazz Pharmaceuticals plc reports a transaction where EVP & Chief Legal Officer Neena M. Patil disposed of shares to cover tax obligations.

Jazz Pharmaceuticals plc executive Philip L. Johnson reported a transaction involving the withholding of shares to cover tax obligations and an acquisition of shares through an employee stock purchase plan.

Jazz Pharmaceuticals director Mark Douglas Smith executed a transaction under a pre-arranged 10b5-1 plan, selling shares at $230.55.

Neena M. Patil, EVP and Chief Legal Officer of Jazz Pharmaceuticals, sold 1,200 ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals CEO Renee Gala donated 600 ordinary shares to a donor-advised fund on June 3, 2026.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported a sale of 6,000 ordinary shares for $235.12 per share, executed under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals plc reports a Form 4 filing detailing a transaction by EVP & Chief Legal Officer Neena M. Patil involving the sale of ordinary shares.

Jazz Pharmaceuticals plc reports a transaction by Director Seamus Mulligan involving the acquisition of ordinary shares and the exercise of a stock option.

Director Rick E. Winningham exercised stock options and sold a portion of the resulting shares in Jazz Pharmaceuticals.

Director Heather Ann McSharry sold 2,000 ordinary shares of Jazz Pharmaceuticals plc at a price of $241 per share.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported a transaction involving the acquisition of 6,000 ordinary shares on May 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported the sale of ordinary shares valued at approximately $190 per share, executed under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 5,900 ordinary shares through a Rule 10b5-1 trading plan on March 3, 2026.